0001185945-13-000001.txt : 20130730 0001185945-13-000001.hdr.sgml : 20130730 20130730122759 ACCESSION NUMBER: 0001185945-13-000001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130723 FILED AS OF DATE: 20130730 DATE AS OF CHANGE: 20130730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OXYGEN BIOTHERAPEUTICS, INC. CENTRAL INDEX KEY: 0000034956 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 262593535 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-806-4414 MAIL ADDRESS: STREET 1: ONE COPLEY PARKWAY STREET 2: SUITE 490 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: SYNTHETIC BLOOD INTERNATIONAL INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SINEQUANON CORP DATE OF NAME CHANGE: 19901219 FORMER COMPANY: FORMER CONFORMED NAME: FEDERATED FRANCHISES INC DATE OF NAME CHANGE: 19760907 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: RALLIS CHRIS A CENTRAL INDEX KEY: 0001185945 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34600 FILM NUMBER: 13994878 MAIL ADDRESS: STREET 1: C/O AEOLUS PHARMACEUTICALS, INC. STREET 2: 26361 CROWN VALLEY PARKWAY, SUITE 150 CITY: MISSION VIEJO STATE: CA ZIP: 92691 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2013-07-23 0 0000034956 OXYGEN BIOTHERAPEUTICS, INC. oxbt 0001185945 RALLIS CHRIS A C/O OXYGEN BIOTHERAPEUTICS, INC. ONE COPLEY PARKWAY SUITE 490 MORRISVILLE NC 27560 1 0 0 0 Series C 8% Convertible Preferred Stock 1.95 2013-07-23 4 P 0 5 A 2013-07-23 common stock 2564 5 D Common Stock Warrants (right to buy) 2.6 2013-07-23 4 P 0 2565 A 2013-07-23 2019-07-23 Common Stock 2565 2565 D The Series C 8% Convertible Preferred Stock has no expiration date. The reported securities are included within 25 Units purchased by the reporting person for $1,000 per Unit. Each Unit consists of (1) a share of Series C 8% Convertible Preferred Stock which is convertible into approximately 512.82 shares of our common stock, and (2) one warrant exercisable for 512.82 shares of common stock at an exercise price of $2.60 per share. /s/ Chris A. Rallis 2013-07-30